Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.
MarketBeat on MSN1h
Despite Challenges Novo Nordisk Plans to Crush GLP-1 CompetitorsNovo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
Novo Nordisk (NVO), the maker of popular obesity/diabetes medications Ozempic and Wegovy, warned Thursday that the Trump ...
Novo Nordisk (NVO), the company behind popular diabetes and weight loss medications Ozempic and Wegovy, warned that President ...
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
Novo Nordisk (NVO) is not concerned by the ongoing ... Novo is also already in North Carolina, with a $2.5 billion API production site, and is building out the next step in the supply chain ...
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
24/7 Wall St. on MSN13d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
European shares were down sharply on Monday, giving up early gains as worries over erratic US tariffs policies dented sentiment.
South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.
Zacks.com on MSN2d
Novo Nordisk (NVO) Stock Dips While Market Gains: Key FactsIn the latest market close, Novo Nordisk (NVO) reached $87.17, with a -0.99% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.55% for the day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback